Biopharma | May 05, 2026
Zydus Lifesciences subsidiary faces Rs 9 million GST demand notice
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Former Wavemaker executive to lead media strategy and digital transformation agenda
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
Subscribe To Our Newsletter & Stay Updated
